There’s no denying the popularity of weight-loss drugs in the United States, with one in eight adults relying on GLP-1s to ...

By Don Thompson for KFF Health News. Broadcast version by Suzanne Potter for California News Service reporting for the KFF ...

According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020.

A recent poll highlights how the pursuit of weight loss has quietly become a costly, long-term financial burden for many ...

The diabetes and weight?loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025. According to global health information technology ...

Amycretin targets GLP-1 and amylin hormones, seen as potential best-in-class therapy Novo shares rise over 5% after amycretin trial results Amycretin aids significant weight loss and glucose control ...

Weight loss journeys are as unique as the individuals who embark on them. We all have different body types, lifestyles, health histories and goals that shape what we need to achieve lasting results.

Please provide your email address to receive an email when new articles are posted on . On average, people who stopped using weight loss drugs regained 0.4 kg monthly. The weight lost during treatment ...

The increasing use of weight loss drugs will result in a sizeable drop in demand for food products. So how will the food industry react?

“Weight-loss methods, whether with pharmacotherapy or surgery, have to be mindful to avoid inducing these complications,” ...

Nearly 115 million American adults, more than one in three aged 18 and older, have prediabetes, a condition where blood sugar ...